<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271791</url>
  </required_header>
  <id_info>
    <org_study_id>42352</org_study_id>
    <secondary_id>20050277</secondary_id>
    <nct_id>NCT00271791</nct_id>
  </id_info>
  <brief_title>Prednisone Treatment for Vestibular Neuronitis</brief_title>
  <official_title>Prednisone Treatment for Vestibular Neuronitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clalit Health Services, Haifa and West Galilee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the value of steroids in the treatment of
      vestibular neuronitis. The potential benefits of steroid therapy would be analyzed by the
      clinical response, self-perceived handicap and laboratory parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vestibular neuronitis is the second most common cause of peripheral vestibulopathy (the first
      being benign paroxysmal positional vertigo) with incidence of about 3.5/100000. Currently
      vestibular neuronitis is explained by a viral pathogenesis.

      Vestibular neuronitis is considered to have a benign course. The static rotatory vertigo and
      disequilibrium, present even when the patient is completely at rest, subside in most cases
      within a few days, and a gradual return to daily activities is the rule. However, it has been
      shown that there is generally incomplete restoration of peripheral function, and clinical
      recovery is achieved by proprioceptive and visual substitution for the unilateral vestibular
      deficit, combined with central vestibular compensation of the imbalance in vestibular tone.
      Although vestibular neuronitis is usually restricted to one attack, several studies have
      reported continuous or episodic vertigo or unsteadiness in 43% -53% of patients. The main
      residua include impaired vision and disequilibrium during walking and especially during head
      movement toward the affected ear. The rate of positive finding on vestibular evaluation may
      reach 60%. However, vestibular impairment as reflected by positive bedside testing and
      vestibular laboratory evaluation is not necessarily accompanied by subjective complaints and
      does not always reflect the level of incapacity.

      The assumed HSV-1 etiology of vestibular neuronitis and the reported benefit of the
      combination of steroids and acyclovir in Bell's palsy suggest similar advantage in the
      treatment of vestibular neuronitis. Also, glucocorticoid receptors activation was reported to
      enhance vestibular compensation after acute peripheral vestibular insults in various animal
      models. A recent study investigated the effect of prednisolone versus valacyclovir and
      placebo on canal paresis in vestibular neuronitis patients. It was found that steroid
      treatment significantly improved peripheral vestibular function to the extent reflected by
      the caloric testing. However, bedside findings, patients' complaints and daily handicap were
      not evaluated. The relevance of the EOG caloric test results to clinical improvement could be
      argued in light of a previous report showing no correlation between EOG findings and residual
      symptoms in a long-term follow-up of vestibular neuronitis patients, and the finding that
      corticosteroid therapy had no effect on symptoms despite significant recovery of the
      caloric-test results.

      The purpose of the study:

      Prospective controlled longitudinal 12-month evaluation of the value of steroids in the
      treatment of vestibular neuronitis. The potential benefits of steroid therapy would be
      analyzed by the clinical response, self-perceived handicap and EOG laboratory parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical: The presence of static and dynamic nystagmus, positional and positioning nystagmus, and disequilibrium on bedside examination.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional: Scores on the Dizziness Handicap Inventory questionnaires.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory: Caloric lateralization and directional preponderance on electro-oculography (EOG).</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Vestibular Diseases</condition>
  <condition>Vestibular Neuronitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>PO, Placebo, 17 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of vestibular neuronitis.

          -  Documentation of unilateral reduced caloric response (caloric asymmetry &gt;25%) on the
             EOG caloric study.

        Exclusion Criteria:

          -  Complaints of new hearing loss, tinnitus, or neurological deficits.

          -  The presence of previously non-diagnosed sensorineural hearing loss (SNHL)

          -  History of vestibular dysfunction.

          -  Patient younger than 18 years of age.

          -  Known contra-indication to systemic steroids: Unbalanced hypertension, un-controlled
             diabetes mellitus, immunodeficiency, active peptic disease, and avascular necrosis of
             the femoral head.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avi Shupak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Medical Center and Clalit Health Services, Haifa and West Galilee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Itzhak Braverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hillel Yaffe Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avishai Golz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elhanan Greenberg, ND</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avi Shupak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Carmel Medical Center and Clalit Health Services, Haifa and West Galilee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit of Otolaryngology Head and Neck Surgery, Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Otolaryngology Head and Neck Surgery, Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Otolaryngology Head and Neck Surgery, Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otoneurolgy Unit, Lin Medical Center, Clalit Health Services</name>
      <address>
        <city>Haifa</city>
        <zip>35152</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <reference>
    <citation>Strupp M, Zingler VC, Arbusow V, Niklas D, Maag KP, Dieterich M, Bense S, Theil D, Jahn K, Brandt T. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med. 2004 Jul 22;351(4):354-61.</citation>
    <PMID>15269315</PMID>
  </reference>
  <reference>
    <citation>Ohbayashi S, Oda M, Yamamoto M, Urano M, Harada K, Horikoshi H, Orihara H, Kitsuda C. Recovery of the vestibular function after vestibular neuronitis. Acta Otolaryngol Suppl. 1993;503:31-4.</citation>
    <PMID>8470496</PMID>
  </reference>
  <reference>
    <citation>Ariyasu L, Byl FM, Sprague MS, Adour KK. The beneficial effect of methylprednisolone in acute vestibular vertigo. Arch Otolaryngol Head Neck Surg. 1990 Jun;116(6):700-3.</citation>
    <PMID>2187486</PMID>
  </reference>
  <reference>
    <citation>Arbusow V, Schulz P, Strupp M, Dieterich M, von Reinhardstoettner A, Rauch E, Brandt T. Distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis. Ann Neurol. 1999 Sep;46(3):416-9.</citation>
    <PMID>10482275</PMID>
  </reference>
  <reference>
    <citation>Bergenius J, Perols O. Vestibular neuritis: a follow-up study. Acta Otolaryngol. 1999;119(8):895-9.</citation>
    <PMID>10728930</PMID>
  </reference>
  <reference>
    <citation>Shupak A, Nachum Z, Stern Y, Tal D, Gil A, Gordon CR. Vestibular neuronitis in pilots: follow-up results and implications for flight safety. Laryngoscope. 2003 Feb;113(2):316-21.</citation>
    <PMID>12567089</PMID>
  </reference>
  <reference>
    <citation>Cameron SA, Dutia MB. Lesion-induced plasticity in rat vestibular nucleus neurones dependent on glucocorticoid receptor activation. J Physiol. 1999 Jul 1;518(Pt 1):151-8.</citation>
    <PMID>10373697</PMID>
  </reference>
  <reference>
    <citation>Fife TD, Tusa RJ, Furman JM, Zee DS, Frohman E, Baloh RW, Hain T, Goebel J, Demer J, Eviatar L. Assessment: vestibular testing techniques in adults and children: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2000 Nov 28;55(10):1431-41. Review.</citation>
    <PMID>11094095</PMID>
  </reference>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2006</study_first_submitted>
  <study_first_submitted_qc>January 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2006</study_first_posted>
  <last_update_submitted>November 4, 2007</last_update_submitted>
  <last_update_submitted_qc>November 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2007</last_update_posted>
  <keyword>Vestibular Neuronitis</keyword>
  <keyword>Vestibular Function Tests</keyword>
  <keyword>Vestibular Adaptation</keyword>
  <keyword>Steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vestibular Diseases</mesh_term>
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Vestibular Neuronitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

